Biomea Fusion Inc (BMEA) News

Form 8-K - Current report

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean...

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a...

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to...

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated...

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a...

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the...

Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

Icovamenib Achieves a Mean Reduction in HbA1c Greater than 1% at Week 26 Following 4 Weeks of Dosing in Type 2...

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the...

Form 8-K - Current report

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Preclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

U.S. Food and Drug Administration (FDA) lifted Clinical Hold on COVALENT-111 (Type 2 Diabetes) &...

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a...